^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg when given as Neoadjuvant Treatment in Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0)
Excerpt:
...Histologically/cytologically confirmed invasive breast cancer, ER positive as defined by the local laboratory3. ...
Trial ID:
Source:
Title:
Imaging of the effects of fulvestrant on the availability of estrogen receptor binding sites in patients with metastatic breast cancer
Excerpt:
...Patients with a history of histological proven ER-positive primary breast cancer and, whenever available, histological proven ER-positive recurrence. ...
Trial ID:
Less C2 evidence
Source:
Title:
Estrogen receptor blockade and radiation therapy cooperate to enhance the response of immunologically cold ER+ breast cancer to immunotherapy
Published date:
06/13/2023
Excerpt:
We tested whether fulvestrant improved tumor response and animal survival when added to the combination of RT and ICI….In contrast to the minimal effects of ICIs when co-treated with either fulvestrant or RT alone, combinatorial treatment with fulvestrant, RT and ICIs significantly reduced tumor growth and prolonged survival....A combination of RT and fulvestrant can overcome the immunosuppressive TME in a preclinical model of ER+ breast cancer, enhancing the anti-tumor response and increasing the response to ICIs...
DOI:
https://doi.org/10.1186/s13058-023-01671-y
